Pharma Showdown: Should You Buy GlaxoSmithKline plc Or Shire PLC?

Should you buy GlaxoSmithKline plc (LON: GSK) or Shire PLC (LON: SHP)?

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

If you’re struggling to choose between GlaxoSmithKline (LSE: GSK) and Shire (LSE: SHP), you’re not alone.

Glaxo and Shire are two of the UK’s premier pharmaceutical companies, with their individual strengths and weaknesses. 

And choosing between the two is a tough task.  

Lacklustre growth 

There’s only one way to describe Glaxo’s growth: slow and steady.

Management expects 2015 core earnings per share to decline at a percentage rate “in the high teens” as sales of key drugs continue to fall.

However, new treatments will start to work their way through the company’s treatment pipeline by 2016.

As sales of these new products begin to grow, management believes that group’s revenue will grow at a low-to-mid single digit percentage per annum from 2016 to 2020. Core earnings per share are expected to expand at a rate in the mid-to-high single digits during the same period. 

High income 

As I’ve mentioned before, according to my figures, assuming a 7% per annum growth rate through to 2020, Glaxo is on track to earn 111p per share for full-year 2020. 

This indicates that Glaxo is trading at a 2020 P/E of 13.2, which seems expensive for such lacklustre growth. 

Still, Glaxo’s dividend yield makes up for the company’s lack of growth. Based on current figures, Glaxo currently supports a dividend yield of 5.7% and the payout is covered 1.2 times by earnings per share. Management has stated that the company’s dividend payout will be maintained at 80p per share for the next three years. 

So overall, for income investors, Glaxo is a top pick, although growth investors will be left wanting more.  

On the other hand, Shire is a top growth stock.

Accelerating growth 

Over the past five years, Shire’s growth has exploded. Indeed, City analysts expect the company to report earnings per share of 247p for 2015, 250% higher than the figure reported for 2010. 

But the company is not content with this impressive organic growth rate. Management is on the hunt for acquisitions to boost growth and it has been reported that Shire recently made a £12bn bid for its peer, Actelion of Switzerland. 

According to news reports, Actelion — which makes treatments for rare diseases — has rejected Shire’s initial approaches. However, there’s nothing to stop Shire coming back and making another offer. 

Shire has already completed one acquisition this year, a $5.2bn deal for NPS Pharmaceuticals. NPS specialises in treatments for rare diseases and one has one drug approval for sale at present.

Costly shares 

Excluding extraordinary items, Shire’s earnings per share are set to expand by a high double-digit percentage this year. Further growth of 17% is expected during 2016. 

Unfortunately, this means that the market has placed a high valuation on the company’s shares. 

Shire is currently trading at a forward P/E of 21.9 and a 2016 P/E of 18.9. However, the company’s dividend yield leaves a lot to be desired.

Shire offers a token yield of 0.3%, although the payout is covered 24x by earnings per share. According to analysts, Shire’s payout is set to grow by 50% during the next two years as Shire returns more cash to investors. 

It’s up to you

Overall, Shire and Glaxo are two different companies for two different types of investors. Shire is a growth stock, with its best days ahead of it. Glaxo has become the perfect stock for income investors, although the company’s glacial growth rate leaves much to be desired.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns shares of GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Passive income text with pin graph chart on business table
Investing Articles

Yields of up to 7%! I’d consider boosting my income with these FTSE dividend stocks

The London market has some decent-looking dividend stocks right now, and I’m tempted by these two for growing income streams.

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

I’d put £20K in an ISA now to target a £1,900 monthly second income in future!

Christopher Ruane shares why he thinks a long-term approach to investing and careful selection of shares could help him build…

Read more »

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »